Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan (ATCC® 43816)

Type Strain: no  /  Biosafety Level: 2

Application
Control of experimental infections
Respiratory research
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Antigenic Properties Serotype 2
Product Format freeze-dried
Storage Conditions Frozen: -80°C or colder
Freeze-Dried: 2°C to 8°C
Live Culture: See Propagation Section
Preceptrol® no
Type Strain no
Antigenic Properties Serotype 2
Medium ATCC® Medium 3: Nutrient agar or nutrient broth
Growth Conditions
Temperature: 37°C
Atmosphere: Aerobic
Name of Depositor IA Woudenberg-Bakker
Chain of Custody
ATCC <-- IA Woudenberg-Bakker <-- WA Craig <-- KR Comber
References

Bakker-Woudenberg IA, et al. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 28: 654-659, 1985. PubMed: 3911879

Roosendaal R, et al. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob. Agents Chemother. 30: 403-408, 1986. PubMed: 3535664

Roosendaal R, et al. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J. Infect. Dis. 152: 373-378, 1985. PubMed: 3897395

Roosendaal R, et al. Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob. Agents Chemother. 31: 1809-1815, 1987. PubMed: 3324962